Lyra Therapeutics, Inc.
LYRA
SEC CIK 1327273
Follow Lyra Therapeutics
Weekly email: filings, results, news
Revenue, last quarter
$7K
−96.7% vs same quarter last year
Net income
−$7M
+36.7% vs same quarter last year
EPS, diluted
-
Operating cash flow
−$6.1M
+46.6% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $398K | −$28.9M |
| FY24 | $1.5M | −$93.4M |
| FY23 | $1.6M | −$62.7M |
| FY22 | $1.4M | −$55.3M |
| FY21 | $285K | −$43.5M |
| FY20 | - | −$22.1M |
| FY19 | - | −$16.3M |
| FY18 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −7794.5% | −7266.1% |
| FY24 | −6280.8% | −6090.9% |
| FY23 | −4308.1% | −4023.1% |
| FY22 | −4131% | −4055.6% |
| FY21 | −15303.5% | −15267.7% |
| FY20 | - | - |
| FY19 | - | - |
| FY18 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$29M |
| FY24 | −$72.3M |
| FY23 | −$64.4M |
| FY22 | −$43.5M |
| FY21 | −$29.2M |
| FY20 | −$22.9M |
| FY19 | −$14M |
| FY18 | - |
- Lyra Therapeutics
- Healthcare median
Show the numbers
| Year | Lyra Therapeutics | Healthcare median |
|---|---|---|
| FY25 | −7266.1% | 9.8% |
| FY24 | −6090.9% | 10.5% |
| FY23 | −4023.1% | 5.3% |
| FY22 | −4055.6% | 12.7% |
| FY21 | −15267.7% | 10.8% |
| FY20 | - | - |
| FY19 | - | - |
| FY18 | - | - |
News
No stories filed under Lyra Therapeutics yet - coverage appears here as the news feed clusters it.